2. Signaling Pathways
  3. GPCR/G Protein
    Neuronal Signaling
  4. Somatostatin Receptor
  5. Somatostatin Receptor Ligand

Somatostatin Receptor Ligand

Somatostatin Receptor Isoform Comparison

Somatostatin Receptor Ligands (4):

Cat. No. Product Name Effect Purity
  • HY-P11655
    NOTA-TATE
    		Ligand
    NOTA-TATE is a somatostatin receptor 2 (SSTR2) binder. NOTA-TATE binds to SSTR2 to enable targeting of SSTR2-positive tumour cells for PET imaging. NOTA-TATE can be used for the research of neuroendocrine tumours.
  • HY-P10239
    Tyr3-Octreotate
    		Ligand 99.76%
    Tyr3-Octreotate is a ligand for somatostatin receptor subtype 2 (sst2), with an IC50 value of 1.3 nM against sst2 when labeled with [111In-DTPA], and an IC50 value of 1.6 nM against sst2 when labeled with [90Y-DOTA]. Radiolabeled Tyr3-Octreotate generates cell-associated radioactivity, and acts as both a tumor growth inhibitor and a tumor cytotoxic agent. When radiolabeled with 177Lu or 90Y, Tyr3-Octreotate serves as a peptide receptor radionuclide therapy (PRRT) analog. Tyr3-Octreotate can be used in studies related to pancreatic tumors.
  • HY-114133
    Depreotide
    		Ligand
    Depreotide is a nove tumor tarcer, can be complexed with technetium-99m (99mTc-depreotide) for optimal imaging properties. 99mTc-depreotide somatostain receptor imaging has been playing an important role in medical diagnosis research. Depreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
  • HY-P11488
    JR11-PEG3-DOTA-PSMA-03
    		Ligand
    JR11-PEG3-DOTA-PSMA-03 (Compound 2) is an RDC-related compound containing the chelating agent DOTA (HY-W053583), the JR11 peptide (SSTR2 antagonist), and the PSMA ligand. JR11-PEG3-DOTA-PSMA-03 shows SSTR2-binding affinities and PSMA-binding affinities, with IC50 s of 94.0 nM, 81.8 nM, respectively. JR11-PEG3-DOTA-PSMA-03 can be radiolabeled with [68Ga]. [68Ga] radiolabeled JR11-PEG3-DOTA-PSMA-03 can be used in diagnostic studies of neuroendocrine differentiated prostate cancer.